Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.48−0.23 (-0.22%)
Close on Nov 18, 2026Market cap $180.79BP/E 33.6Yield 2.30%
Abbott Laboratories revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Abbott Laboratories's revenue for the twelve months ending Jun 30, 2026 was $46.59B, up 8.1% year over year. For fiscal 2025 it was $44.33B, up 5.7% from the year before. Over ten years it grew 8.1% a year on average. The highest annual figure on record is $44.33B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.33B | +5.7% |
| FY2024 | Dec 31, 2024 | $41.95B | +4.6% |
| FY2023 | Dec 31, 2023 | $40.11B | -8.1% |
| FY2022 | Dec 31, 2022 | $43.65B | +1.3% |
| FY2021 | Dec 31, 2021 | $43.08B | +24.5% |
| FY2020 | Dec 31, 2020 | $34.61B | +8.5% |
| FY2019 | Dec 31, 2019 | $31.90B | +4.3% |
| FY2018 | Dec 31, 2018 | $30.58B | +11.6% |
| FY2017 | Dec 31, 2017 | $27.39B | +31.3% |
| FY2016 | Dec 31, 2016 | $20.85B | +2.2% |
| FY2015 | Dec 31, 2015 | $20.41B | +0.8% |
| FY2014 | Dec 31, 2014 | $20.25B | +3.0% |
| FY2013 | Dec 31, 2013 | $19.66B | +3.2% |
| FY2012 | Dec 31, 2012 | $19.05B | -11.0% |
| FY2011 | Dec 31, 2011 | $21.41B | -39.1% |
| FY2010 | Dec 31, 2010 | $35.17B | +14.3% |
| FY2009 | Dec 31, 2009 | $30.76B | +4.2% |
| FY2008 | Dec 31, 2008 | $29.53B | +13.9% |
| FY2007 | Dec 31, 2007 | $25.91B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.59B | +13.0% |
| Q1 FY2026 | Mar 31, 2026 | $11.16B | +7.8% |
| Q4 FY2025 | Dec 31, 2025 | $11.46B | +4.4% |
| Q3 FY2025 | Sep 30, 2025 | $11.37B | +6.9% |
| Q2 FY2025 | Jun 30, 2025 | $11.14B | +7.4% |
| Q1 FY2025 | Mar 31, 2025 | $10.36B | +4.0% |
| Q4 FY2024 | Dec 31, 2024 | $10.97B | +7.2% |
| Q3 FY2024 | Sep 30, 2024 | $10.64B | +4.9% |
| Q2 FY2024 | Jun 30, 2024 | $10.38B | +4.0% |
| Q1 FY2024 | Mar 31, 2024 | $9.96B | +2.2% |
| Q4 FY2023 | Dec 31, 2023 | $10.24B | +1.5% |
| Q3 FY2023 | Sep 30, 2023 | $10.14B | -2.6% |
| Q2 FY2023 | Jun 30, 2023 | $9.98B | -11.4% |
| Q1 FY2023 | Mar 31, 2023 | $9.75B | -18.1% |
| Q4 FY2022 | Dec 31, 2022 | $10.09B | -12.0% |
| Q3 FY2022 | Sep 30, 2022 | $10.41B | -4.7% |
| Q2 FY2022 | Jun 30, 2022 | $11.26B | +10.1% |
| Q1 FY2022 | Mar 31, 2022 | $11.90B | +13.8% |
| Q4 FY2021 | Dec 31, 2021 | $11.47B | +7.2% |
| Q3 FY2021 | Sep 30, 2021 | $10.93B | +23.4% |
| Q2 FY2021 | Jun 30, 2021 | $10.22B | +39.5% |
| Q1 FY2021 | Mar 31, 2021 | $10.46B | +35.3% |
| Q4 FY2020 | Dec 31, 2020 | $10.70B | +28.7% |
| Q3 FY2020 | Sep 30, 2020 | $8.85B | +9.6% |
| Q2 FY2020 | Jun 30, 2020 | $7.33B | -8.2% |
| Q1 FY2020 | Mar 31, 2020 | $7.73B | +2.5% |
| Q4 FY2019 | Dec 31, 2019 | $8.31B | +7.1% |
| Q3 FY2019 | Sep 30, 2019 | $8.08B | +5.5% |
| Q2 FY2019 | Jun 30, 2019 | $7.98B | +2.7% |
| Q1 FY2019 | Mar 31, 2019 | $7.54B | +2.0% |
| Q4 FY2018 | Dec 31, 2018 | $7.77B | +2.3% |
| Q3 FY2018 | Sep 30, 2018 | $7.66B | +12.1% |
| Q2 FY2018 | Jun 30, 2018 | $7.77B | +17.0% |
| Q1 FY2018 | Mar 31, 2018 | $7.39B | +16.7% |
| Q4 FY2017 | Dec 31, 2017 | $7.59B | +42.3% |
| Q3 FY2017 | Sep 30, 2017 | $6.83B | +28.8% |
| Q2 FY2017 | Jun 30, 2017 | $6.64B | – |
| Q1 FY2017 | Mar 31, 2017 | $6.34B | – |
| Q4 FY2016 | Dec 31, 2016 | $5.33B | – |
| Q3 FY2016 | Sep 30, 2016 | $5.30B | – |
See a number that looks wrong?